Literature DB >> 14763956

Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features.

G Isoardo1, M Bergui, L Durelli, P Barbero, M Boccadoro, A Bertola, P Ciaramitaro, A Palumbo, B Bergamasco, D Cocito.   

Abstract

OBJECTIVE: Thalidomide is a promising therapy for multiple myeloma. Sensory neuropathy is a side effect of thalidomide and resulted to be partially reversible in 50% of cases, suggesting a sensory ganglionopathy. Spinal cord magnetic resonance imaging (MRI) was found to be useful in the diagnosis of sensory ganglionopathies and we use it to determine if thalidomide neuropathy has features of a ganglionopathy.
MATERIAL AND METHODS: Six patients with multiple myeloma developed thalidomide-induced polyneuropathy. Nerve conduction studies, somatosensory-evoked potentials (SEPs) and cervical and dorsal spinal cord MRI were obtained in all.
RESULTS: All patients had a sensory neuropathy, with clinical or electrophysiological abnormalities involving all four limbs. Spinal cord MRI showed high signal intensity in the posterior columns in only one patient, with abnormal central conduction time at SEPs.
CONCLUSION: Our results suggest that thalidomide can induce either an axonal length-dependent neuropathy or, less frequently, a ganglionopathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14763956     DOI: 10.1034/j.1600-0404.2003.00203.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  10 in total

Review 1.  Neurologic toxicities of cancer therapies.

Authors:  Robert Cavaliere; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

2.  Incidence of paraneoplastic polyneuropathies associated with non-Hodgkin lymphoma in the province of Asti, Italy.

Authors:  Gianluca Isoardo; Elisabetta Campa; Giuseppe Migliaretti; Walter Troni
Journal:  J Neurol       Date:  2007-01-27       Impact factor: 4.849

Review 3.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 4.  The double-edged sword: Neurotoxicity of chemotherapy.

Authors:  Rajiv S Magge; Lisa M DeAngelis
Journal:  Blood Rev       Date:  2014-09-28       Impact factor: 8.250

Review 5.  Advances in understanding drug-induced neuropathies.

Authors:  Amanda C Peltier; James W Russell
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 6.  A Comparative Review of Chemotherapy-Induced Peripheral Neuropathy in In Vivo and In Vitro Models.

Authors:  Sandy Eldridge; Liang Guo; John Hamre
Journal:  Toxicol Pathol       Date:  2019-07-22       Impact factor: 1.902

Review 7.  Chemotherapy-Related Neurotoxicity.

Authors:  Sophie Taillibert; Emilie Le Rhun; Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2016-09       Impact factor: 5.081

8.  Central neurotoxicity of immunomodulatory drugs in multiple myeloma.

Authors:  Urmeel H Patel; Muhammad A Mir; Jeffrey K Sivik; Divisha Raheja; Manoj K Pandey; Giampaolo Talamo
Journal:  Hematol Rep       Date:  2015-03-03

Review 9.  From the Bottom-Up: Chemotherapy and Gut-Brain Axis Dysregulation.

Authors:  Juliana E Bajic; Ian N Johnston; Gordon S Howarth; Mark R Hutchinson
Journal:  Front Behav Neurosci       Date:  2018-05-22       Impact factor: 3.558

Review 10.  Mitochondrial Dysfunction in Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Authors:  Annalisa Canta; Eleonora Pozzi; Valentina Alda Carozzi
Journal:  Toxics       Date:  2015-06-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.